Immuto Scientific Health false
3 known investors
Immuto Scientific uses a patented, AI-enabled structural proteomics and mass spectrometry platform to characterize disease-specific surface protein conformations and identify novel targetable epitopes. The company applies this approach to discover targets for cancer therapeutics.
AI & Machine LearningBiotechDeep Tech
Investors · 3
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $321.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Immuto Scientific Health false do?
- Immuto Scientific uses a patented, AI-enabled structural proteomics and mass spectrometry platform to characterize disease-specific surface protein conformations and identify novel targetable epitopes. The company applies this approach to discover targets for cancer therapeutics.
- Who are Immuto Scientific Health false's investors?
- Immuto Scientific Health false's investors include DYDX Capital, Great Oaks Venture Capital, Tundra Angels.